tamoxifen
Commercial- Indications
- Breast cancer
Company intelligence / Profile preview
At the time of its acquisition by Teva in December 2008 for $7.5–$8.9 billion, Barr was the fourth largest generic drug company in the US with a strong presence in women’s health and a broad portfolio of both generic and proprietary pharmaceuticals. The company had recently expanded globally through acquisitions such as PLIVA. Its integration into Teva created one of the world’s largest generics businesses.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Barr Pharmaceuticals.